Last quarter (Q4 2021), Shield Therapeutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Shield Therapeutics's net income was £―. See Shield Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	£ 5.17M	£ 1.52M	£ 10.39M	£ 719.00K	£ 11.88M
Cost of Revenue	-	£ 2.47M	£ 980.00K	£ 1.35M	£ 485.00K	£ 311.00K
Gross Profit	-	£ 2.70M	£ 539.00K	£ 9.03M	£ 234.00K	£ 11.57M
Operating Expense	-	£ 43.11M	£ 20.49M	£ 11.19M	£ 9.27M	£ 16.73M
Operating Income	-	£ -40.41M	£ -19.95M	£ -2.15M	£ -9.04M	£ -5.16M
Net Non Operating Interest Income Expense	-	£ -359.00K	£ -5.00K	£ -2.00K	£ 16.00K	£ -22.00K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ -40.08M	£ -19.57M	£ -1.89M	£ -9.07M	£ -5.15M
Tax Provision	-	£ 362.00K	£ -229.00K	£ 744.00K	£ -266.00K	£ -3.36M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -40.44M	£ -19.34M	£ -2.63M	£ -8.80M	£ -1.79M
Basic EPS	-	£ -0.17	£ -0.09	£ -0.02	£ -0.08	£ -0.02
Diluted EPS	-	£ -0.17	£ -0.09	£ -0.02	£ -0.08	£ -0.02
Basic Average Shares	-	£ 233.19M	£ 204.02M	£ 117.23M	£ 116.99M	£ 116.43M
Diluted Average Shares	-	£ 233.19M	£ 204.02M	£ 117.23M	£ 116.99M	£ 116.43M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	£ 175.00K	£ 333.00K
Total Expenses	-	£ 45.58M	£ -21.47M	£ -12.54M	£ 9.75M	£ 17.04M
Net Income From Continuing And Discontinued Operation	-	£ -40.44M	£ -19.34M	£ -2.63M	£ -8.80M	£ -1.79M
Normalized Income	-	£ -32.47M	£ -19.79M	£ -1.53M	£ -8.80M	£ -1.79M
Interest Expense	-	-	-	-	£ 1.00K	£ 29.00K
EBIT	-	£ -39.69M	£ -19.57M	£ -1.89M	£ -9.06M	£ -5.12M
EBITDA	-	£ -37.33M	£ -19.57M	£ -1.89M	£ -6.44M	£ -2.43M

Currency in GBP

Shield Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing